on and antigen levels in blood increased with C1-INH treatment [C1 function (p=0.0007) and C1-INH antigen percent (p=0.013)]. Patients treated with C1-INH experienced increased C3 levels on day 30 (p=0.005), while C4 levels were significantly higher at all time points. During the study period, no patient treated with C1-INH developed antibody-mediated rejection. Twenty percent of patients developed antibody-mediated rejection following the study period. Thirty percent of patients treated with placebo developed antibody-mediated rejection, ten percent during the study period.
This Investigator-Initiated Research study was supported by CSL Behring.
About Antibody-Mediated Rejection
Antibody-mediated rejection is a major cause of kidney transplant failure and a prime barrier to improving long-term outcomes for transplant patients. The types of antibody-mediated rejection vary in acuity and severity. Approximately 10 to 15 percent of kidney recipients experience rejection within one year after transplantation.
About CSL Behring
CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide.
CSL Behring therapies are used around the world to treat coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease, and neurological disorders in certain markets. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in the newborn. CSL Behring is a subsidiary of CSL Limited, a biopharmaceutical company with headquarters in Melbourne, Australia. For more information, visit Page: 1 2 3 Related biology technology :1
. Positive Clinical Study Results for BSPs HyperQ Technology2
. 15-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting3
. DermTechs Non-invasive Melanoma Detection Assay Poised to Enter Clinical Validation Study4
. Marshall study shows nanoparticles used as additives in diesel fuels can travel from lungs to liver5
. Clionsky Neuro Systems (CNS-Neuro) Announces Publication of Study Finding Elderly Patients Unable to Recognize Their Memory Loss6
. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV21979447
. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation8
. Singapore scientists lead human embryonic stem cell study9
. GeneTex Antibody Company to Launch New Line of Primary Antibodies for the Study of Spindle Assembly10
. Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain11
. Metabolex Announces Positive Results From its Clinical Study of Arhalofenate in Combination With Febuxostat